Identification the Molecular Mechanisms that Explain a Novel Histone Deacetylase Inhibitor OBP-801 Sensitivity in Human Cancer

被引：0
|
作者：
Ooizumi, Y. [1 ]
Yamashita, K. [1 ]
Kazuko, Y. [1 ]
Igarashi, K. [1 ]
Kojima, K. [1 ]
Katoh, H. [1 ]
Yamanashi, T. [1 ]
Sato, T. [1 ]
Nakamura, T. [1 ]
Watanabe, M. [1 ]
机构：
[1] Kitasato Univ, Sch Med, Sagamihara, Kanagawa, Japan
来源：
ANNALS OF SURGICAL ONCOLOGY | 2018年 / 25卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
PF181
引用
收藏
页码：S206 / S206
页数：1
相关论文
共 50 条
  • [1] The Novel Histone Deacetylase Inhibitor, OBP-801, Induces Apoptosis in Rhabdoid Tumors by Releasing the Silencing of NOXA
    Sugimoto, Yohei
    Katsumi, Yoshiki
    Iehara, Tomoko
    Kaneda, Daisuke
    Tomoyasu, Chihiro
    Ouchi, Kazutaka
    Yoshida, Hideki
    Miyachi, Mitsuru
    Yagyu, Shigeki
    Kikuchi, Ken
    Tsuchiya, Kunihiko
    Kuwahara, Yasumichi
    Sakai, Toshiyuki
    Hosoi, Hajime
    MOLECULAR CANCER THERAPEUTICS, 2020, 19 (10) : 1992 - 2000
  • [2] OBP-801, a novel histone deacetylase inhibitor, induces M-phase arrest and apoptosis in rhabdomyosarcoma cells
    Tomoyasu, Chihiro
    Kikuchi, Ken
    Kaneda, Daisuke
    Yagyu, Shigeki
    Miyachi, Mitsuru
    Tsuchiya, Kunihiko
    Iehara, Tomoko
    Sakai, Toshiyuki
    Hosoi, Hajime
    ONCOLOGY REPORTS, 2019, 41 (01) : 643 - 649
  • [3] The histone deacetylase inhibitor OBP-801 has in vitro/in vivo anti-neuroblastoma activity
    Kaneda, Daisuke
    Iehara, Tomoko
    Kikuchi, Ken
    Sugimoto, Yohei
    Nakagawa, Norio
    Yagyu, Shigeki
    Miyachi, Mitsuru
    Konishi, Eiichi
    Sakai, Toshiyuki
    Hosoi, Hajime
    PEDIATRICS INTERNATIONAL, 2022, 64 (01)
  • [4] The Histone Deacetylase Inhibitor OBP-801 Exhibits Potent Anti-Tumor Activity Against Neuroblastoma
    Kaneda, Daisuke
    Kikuchi, Ken
    Yagyu, Shigeki
    Iehara, Tomoko
    Sakai, Toshiyuki
    Hosoi, Hajime
    PEDIATRIC BLOOD & CANCER, 2018, 65 : S40 - S41
  • [5] A histone deacetylase inhibitor OBP-801 and eribulin synergistically inhibit the growth with apoptosis in triple-negative breast cancer cells
    Ono, Hisako
    Sowa, Yoshihiro
    Iizumi, Yosuke
    Horinaka, Mano
    Taguchi, Tetsuya
    Sakai, Toshiyuki
    CANCER RESEARCH, 2018, 78 (13)
  • [6] OBP-801, a novel histone deacetylase inhibitor, induces M-phase arrest and apoptosis in rhabdomyosarcoma cells (vol 41, pg 643, 2019)
    Tomoyasu, Chihiro
    Kikuchi, Ken
    Kaneda, Daisuke
    Yagyu, Shigeki
    Miyachi, Mitsuru
    Tsuchiya, Kunihiko
    Iehara, Tomoko
    Sakai, Toshiyuki
    Hosoi, Hajime
    ONCOLOGY REPORTS, 2019, 41 (04) : 2601 - 2601
  • [7] A Histone Deacetylase Inhibitor, OBP-801, and Celecoxib Synergistically Inhibit the Cell Growth with Apoptosis via a DR5-Dependent Pathway in Bladder Cancer Cells
    Toriyama, Seijiro
    Horinaka, Mano
    Yasuda, Shusuke
    Taniguchi, Tomoyuki
    Aono, Yuichi
    Takamura, Toshiya
    Morioka, Yukako
    Miki, Tsuneharu
    Ukimura, Osamu
    Sakai, Toshiyuki
    MOLECULAR CANCER THERAPEUTICS, 2016, 15 (09) : 2066 - 2075
  • [8] Phase Ia dose escalation study of OBP-801, a cyclic depsipeptide class I histone deacetylase inhibitor, in patients with advanced solid tumors
    Heath, Elisabeth I.
    Weise, Amy
    Vaishampayan, Ulka
    Danforth, Dailan
    Ungerleider, Richard S.
    Urata, Yasuo
    INVESTIGATIONAL NEW DRUGS, 2022, 40 (02) : 300 - 307
  • [9] Phase Ia dose escalation study of OBP-801, a cyclic depsipeptide class I histone deacetylase inhibitor, in patients with advanced solid tumors
    Elisabeth I. Heath
    Amy Weise
    Ulka Vaishampayan
    Dailan Danforth
    Richard S. Ungerleider
    Yasuo Urata
    Investigational New Drugs, 2022, 40 : 300 - 307
  • [10] The novel combination treatment of a HDAC inhibitor OBP-801 with eribulin for triple-negative breast cancer cells
    Ono, Hisako
    Sowa, Yoshihiro
    Horinaka, Mano
    Iizumi, Yosuke
    Watanabe, Motoki
    Taguchi, Tetsuya
    Sakai, Toshiyuki
    CANCER SCIENCE, 2018, 109 : 559 - 559
12345